[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 54, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 66, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 905293, "exercisedValue": 0, "unexercisedValue": 219686}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Mr. Roy M. Gonzales CPA, M.B.A.", "age": 48, "title": "Senior VP of Finance and Principal Financial & Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark S. Forman M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Snehal  Naik Ph.D.", "title": "Senior VP of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kye  Gilder M.D.", "title": "SVP of Biometrics - Biostatistics, Data Management, Statistical Programming, Medical Writing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathy  Ogilvie Ph.D.", "title": "Senior VP of Translational & Nonclinical Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rosa  Ferrao", "title": "Senior VP of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.45, "open": 1.49, "dayLow": 1.41, "dayHigh": 1.615, "regularMarketPreviousClose": 1.45, "regularMarketOpen": 1.49, "regularMarketDayLow": 1.41, "regularMarketDayHigh": 1.61, "payoutRatio": 0.0, "forwardPE": -0.7348837, "volume": 1219184, "regularMarketVolume": 1219184, "averageVolume": 1656150, "averageVolume10days": 898800, "averageDailyVolume10Day": 898800, "bid": 1.54, "ask": 1.6, "bidSize": 20, "askSize": 13, "marketCap": 112385552, "fiftyTwoWeekLow": 1.41, "fiftyTwoWeekHigh": 11.48, "fiftyDayAverage": 2.0022, "twoHundredDayAverage": 2.46665, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "sharesOutstanding": 71130096, "sharesShort": 6623831, "sharesShortPriorMonth": 6682970, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.0937, "heldPercentInsiders": 0.04464, "heldPercentInstitutions": 0.86926, "shortRatio": 4.39, "shortPercentOfFloat": 0.1097, "impliedSharesOutstanding": 70710704, "bookValue": 3.945, "priceToBook": 0.400507, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -135122000, "trailingEps": -1.97, "forwardEps": -2.15, "52WeekChange": -0.8388889, "SandP52WeekChange": 0.16050637, "quoteType": "EQUITY", "currentPrice": 1.58, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.5, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "ebitda": -148182000, "debtToEquity": 3.959, "returnOnEquity": -0.51702, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VTYX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "averageDailyVolume3Month": 1656150, "fiftyTwoWeekLowChange": 0.17000008, "fiftyTwoWeekLowChangePercent": 0.12056743, "fiftyTwoWeekRange": "1.41 - 11.48", "fiftyTwoWeekHighChange": -9.9, "fiftyTwoWeekHighChangePercent": -0.86236936, "fiftyTwoWeekChangePercent": -83.888885, "earningsTimestamp": 1740690301, "earningsTimestampStart": 1740690301, "earningsTimestampEnd": 1740690301, "earningsCallTimestampStart": 1715286600, "earningsCallTimestampEnd": 1715286600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.97, "epsForward": -2.15, "epsCurrentYear": -1.985, "priceEpsCurrentYear": -0.7959698, "fiftyDayAverageChange": -0.42219985, "fiftyDayAverageChangePercent": -0.21086799, "twoHundredDayAverageChange": -0.88664997, "twoHundredDayAverageChangePercent": -0.3594551, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-21", "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": 8.965517, "regularMarketPrice": 1.58, "corporateActions": [], "postMarketTime": 1740790516, "regularMarketTime": 1740776401, "exchange": "NMS", "messageBoardId": "finmb_672535556", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634823000000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.58, "postMarketChange": 0.0, "regularMarketChange": 0.13, "regularMarketDayRange": "1.41 - 1.61", "fullExchangeName": "NasdaqGS", "displayName": "Ventyx Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]